JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wong, P. C.
Right arrow Articles by Slee, A. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wong, P. C.
Right arrow Articles by Slee, A. M.

Vol. 295, Issue 1, 212-218, October 2000

Nonpeptide Factor Xa Inhibitors II. Antithrombotic Evaluation in a Rabbit Model of Electrically Induced Carotid Artery Thrombosis1

Pancras C. Wong, Earl J. Crain, Robert M. Knabb, Raymond P. Meade, Mimi L. Quan, Carol A. Watson, Ruth R. Wexler, Matthew R. Wright2 and Andrew M. Slee

Cardiovascular Diseases Research (P.C.W., E.J.C., R.M.K., R.P.M., C.A.W., A.M.S.), Chemical and Physical Sciences (M.L.Q., R.R.W.), Drug Metabolism and Pharmacokinetics (M.R.W.), DuPont Pharmaceuticals Company, Wilmington, Delaware

SK549 (mol. wt. 546 Da) is a synthetic, selective inhibitor of human coagulation factor Xa (fXa) (Ki = 0.52 nM). This study compared the antithrombotic effects of SK549 and a series of benzamidine isoxazoline fXa inhibitors with aspirin, DuP 714 (a direct thrombin inhibitor), recombinant tick anticoagulant peptide, or heparin in a rabbit model of electrically induced carotid arterial thrombosis. Compounds were infused i.v. continuously from 60 min before electrical stimulation to the end of the experiment. Values of ED50 (dose that increases the carotid blood flow to 50% of the control) were 0.12 µmol/kg/h for SK549, 0.56 µmol/kg/h for aspirin, 0.14 µmol/kg/h for DuP 714, 0.06 µmol/kg/h for recombinant tick anticoagulant peptide, and >100 U/kg/h for heparin. The EC50 (plasma concentration that increased blood flow to 50% of the control) for SK549 was 97 nM. Unlike aspirin and heparin, SK549 was efficacious and, at 1.5 µmol/kg/h i.v. (n = 9), maintained carotid blood flow at 87 ± 6% of control level for greater than 90 min. Unlike heparin, SK549 inhibited ex vivo fXa activity but not ex vivo thrombin activity. There was a highly significant correlation between Ki (fXa) and ED50 of a series of fXa inhibitors (r = 0.85, P < .001). Therefore, these results suggest that SK549 is a novel, potent, and effective antithrombotic agent in a rabbit model of arterial thrombosis. It is likely that SK549 exerts its antithrombotic effect through selective inhibition of fXa. Furthermore, SK549 may be clinically useful for the prevention of arterial thrombosis.


1 Presented in part at the 72nd Scientific Sessions of the American Heart Association, November 7-10, 1999, Atlanta, Georgia (Abstr. 2483).

2 Current address: Tularik, Inc., South San Francisco, CA.


0022-3565/00/2951-0212$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2000 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
P. C. Wong, E. J. Crain, C. A. Watson, A. M. Zaspel, M. R. Wright, P. Y. Lam, D. J. P. Pinto, R. R. Wexler, and R. M. Knabb
Nonpeptide Factor Xa Inhibitors III: Effects of DPC423, an Orally-Active Pyrazole Antithrombotic Agent, on Arterial Thrombosis in Rabbits
J. Pharmacol. Exp. Ther., December 1, 2002; 303(3): 993 - 1000.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2000 by the American Society for Pharmacology and Experimental Therapeutics.